Product Description: SRSF1-IN-1 (STP2) is a SRSF1 inhibitor that regulates the splicing of Bcl-x precursor mRNA by inhibiting SRSF1 expression. SRSF1-IN-1 exhibits anti-tumor activity both in vitro and in vivo, with IC50 values ranging from 0.33 to 6.93 μM against tumor cells such as HepG2 and MCF7. In mice, SRSF1-IN-1 demonstrates good safety, as intraperitoneal injection at 1 g/kg does not cause death or pathological damage. SRSF1-IN-1 holds promising potential for research in the field of anti-tumor therapy[1].
Applications: Cancer-Kinase/protease
Formula: C20H24O5S
References: [1]Chen X, et al. Design and synthesis of novel sulfur-substituted triptolide with the ability to induce autophagy through inhibition of SRSF1 expression. Eur J Med Chem. 2025 Apr 5;287:117342.
Molecular Weight: 376.47
Research Area: Cancer
Target: SRPK
Deutsch
English
